MCID: DFC004
MIFTS: 74

Deficiency Anemia

Categories: Blood diseases, Immune diseases, Respiratory diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Deficiency Anemia

Summaries for Deficiency Anemia

MedlinePlus: 41 If you have anemia, your blood does not carry enough oxygen to the rest of your body. The most common cause of anemia is not having enough iron. Your body needs iron to make hemoglobin. Hemoglobin is an iron-rich protein that gives the red color to blood. It carries oxygen from the lungs to the rest of the body. Anemia has three main causes: blood loss, lack of red blood cell production, and high rates of red blood cell destruction. Conditions that may lead to anemia include: Heavy periods Pregnancy Ulcers Colon polyps or colon cancer Inherited disorders A diet that does not have enough iron, folic acid or vitamin B12 Blood disorders such as sickle cell anemia and thalassemia, or cancer Aplastic anemia, a condition that can be inherited or acquired G6PD deficiency, a metabolic disorder Anemia can make you feel tired, cold, dizzy, and irritable. You may be short of breath or have a headache. Your doctor will diagnose anemia with a physical exam and blood tests. Treatment depends on the kind of anemia you have. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary: Deficiency Anemia, also known as anemia, is related to iron deficiency anemia and diamond-blackfan anemia, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Deficiency Anemia is HBA2 (Hemoglobin Subunit Alpha 2), and among its related pathways/superpathways are Cellular responses to stimuli and Binding and Uptake of Ligands by Scavenger Receptors. The drugs Iron protein succinylate and Proguanil have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, kidney and heart, and related phenotypes are homeostasis/metabolism and liver/biliary system

PubMed Health : 63 Anemia: Anemia (uh-NEE-me-uh) is a condition in which your blood has a lower than normal number of red blood cells. Anemia also can occur if your red blood cells don't contain enough hemoglobin (HEE-muh-glow-bin). Hemoglobin is an iron-rich protein that gives blood its red color. This protein helps red blood cells carry oxygen from the lungs to the rest of the body. If you have anemia, your body doesn't get enough oxygen-rich blood. As a result, you may feel tired or weak. You also may have other symptoms, such as shortness of breath, dizziness, or headaches. Severe or long-lasting anemia can damage your heart, brain, and other organs in your body. Very severe anemia may even cause death.

Disease Ontology: 11 A hematopoietic system disease that is characterized by a decrease in the normal number of red blood cells.

Wikipedia: 75 Anemia or anaemia (British English) is a blood disorder in which the blood has a reduced ability to... more...

Related Diseases for Deficiency Anemia

Diseases related to Deficiency Anemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 3338)
# Related Disease Score Top Affiliating Genes
1 iron deficiency anemia 33.9 TMPRSS6 TFRC HAMP G6PD EPO
2 diamond-blackfan anemia 33.9 TFRC RPS26 RPL11 HAMP GATA1 EPO
3 iron metabolism disease 33.6 TTR TMPRSS6 TFRC HBB HAMP G6PD
4 anemia, congenital dyserythropoietic, type ia 33.6 TFRC SPTA1 HAMP GATA1 EPO
5 hereditary spherocytosis 33.6 TFRC SPTA1 HBB HAMP GATA1 G6PD
6 heinz body anemias 33.3 LOC107133510 LOC106804612 LOC106099062 HBB HBA2 HBA1
7 diamond-blackfan anemia 1 33.3 RPS26 RPL11 GATA1
8 anemia, congenital dyserythropoietic, type ib 33.1 HAMP GATA1 G6PD
9 microcytic anemia 33.1 TMPRSS6 TFRC HBB HBA2 HAMP G6PD
10 anemia, congenital dyserythropoietic, type iiia 33.0 SPTA1 GATA1
11 neonatal anemia 32.9 TFRC HBB HAMP EPO
12 folic acid deficiency anemia 32.8 HAMP EPO
13 beta-thalassemia, dominant inclusion body type 32.8 LOC107133510 LOC106099062 HBB
14 congenital nonspherocytic hemolytic anemia 32.8 SPTA1 G6PD
15 thalassemia 32.6 TMPRSS6 TFRC LOC107133510 LOC106804612 HBB HBA2
16 fetal hemoglobin quantitative trait locus 1 32.6 LOC107133510 LOC106099062 HBB HBA2 HBA1 GATA1
17 hemoglobin h disease 32.6 TFRC LOC106804612 HBB HBA2 HBA1 HAMP
18 glutathione peroxidase deficiency 32.5 HBB HBA2 HBA1
19 erythrocytosis, familial, 8 32.5 HBA2 HBA1
20 aceruloplasminemia 32.5 TMPRSS6 TFRC MT-ATP6 HAMP
21 hydrops fetalis, nonimmune 32.5 LOC106804612 HBA2 HBA1 FOXP3
22 beta-thalassemia 32.4 TMPRSS6 TFRC SPTA1 LOC107133510 LOC106099062 HBB
23 beta-thalassemia intermedia 32.4 TMPRSS6 TFRC HBB HAMP EPO
24 shwachman-diamond syndrome 1 32.3 RPS26 RPL11 GATA1
25 dyskeratosis congenita 32.3 RPS26 RPL11 GATA1 EPO
26 hereditary elliptocytosis 32.3 SPTA1 HBB G6PD
27 nutritional deficiency disease 32.1 TTR TMPRSS6 TFRC HAMP EPO
28 porphyria cutanea tarda 32.1 TFRC HAMP GATA1 EPO
29 hemolytic anemia 32.1 TMPRSS6 TFRC SPTA1 LOC107133510 LOC106099062 HBB
30 hemoglobinopathy 32.0 TMPRSS6 TFRC LOC107133510 LOC106099062 HBB HBA2
31 alpha-thalassemia 32.0 TMPRSS6 TFRC LOC107133510 LOC106804612 LOC106099062 HBB
32 sickle cell anemia 31.9 TFRC LOC107133510 LOC106099062 HBB HBA2 HBA1
33 anemia, sideroblastic, 1 31.9 TMPRSS6 TFRC HBB HAMP GATA1 EPO
34 hypochromic microcytic anemia 31.9 TMPRSS6 TFRC HBB HBA2 HBA1 HAMP
35 iron overload in africa 31.8 TMPRSS6 HAMP
36 hemoglobin d disease 31.7 LOC107133510 HBB
37 thalassemia minor 31.7 HBB HBA2 HBA1 HAMP GATA1 EPO
38 hemochromatosis, type 1 31.7 TMPRSS6 TFRC HBB HBA2 HBA1 HAMP
39 alpha thalassemia-intellectual disability syndrome type 1 31.7 HBA2 HBA1
40 malaria 31.6 TFRC SPTA1 LOC107133510 LOC106099062 HBB HBA2
41 polycythemia 31.5 TFRC HBB HBA2 HBA1 HAMP GATA1
42 splenomegaly 31.5 LOC106804612 HBB HBA2 HBA1 EPO
43 sickle cell disease 31.4 LOC107133510 LOC106099062 HBB HBA2 G6PD EPO
44 hemosiderosis 31.4 TFRC HAMP EPO
45 aplastic anemia 31.3 TFRC RPS26 RPL11 GATA1 EPO
46 glucosephosphate dehydrogenase deficiency 31.3 SPTA1 HBB HBA2 HBA1 G6PD
47 beta-thalassemia major 31.2 TMPRSS6 TFRC LOC107133510 LOC106099062 HBB HBA2
48 congenital hemolytic anemia 31.2 TFRC SPTA1 HBB HBA2 HBA1 HAMP
49 plasmodium vivax malaria 31.1 TFRC GATA1 G6PD
50 sickle cell disease and related diseases 31.1 LOC107133510 LOC106099062 HBB

Comorbidity relations with Deficiency Anemia via Phenotypic Disease Network (PDN): (show top 50) (show all 330)


3-Hydroxyacyl-Coa Dehydrogenase Deficiency Acquired Thrombocytopenia
Active Peptic Ulcer Disease Acute Conjunctivitis
Acute Cystitis Acute Kidney Failure
Acute Leukemia Acute Maxillary Sinusitis
Acute Myocardial Infarction Acute Pancreatitis
Acute Proliferative Glomerulonephritis Acute Vascular Insufficiency of Intestine
Adjustment Disorder Adrenal Gland Disease
Agammaglobulinemia, X-Linked Alcohol Use Disorder
Alcoholic Gastritis Alcoholic Hepatitis
Alcoholic Liver Cirrhosis Alcoholic Neuropathy
Alzheimer Disease, Familial, 1 Amyloidosis
Anemia, Autoimmune Hemolytic Anus Cancer
Anxiety Aortic Aneurysm
Aortic Atherosclerosis Aortic Valve Disease 1
Asbestosis Ascending Colon Cancer
Aspergillosis Atrioventricular Block
Atrophic Gastritis Atypical Depressive Disorder
Autonomic Nervous System Disease Bacteremia 2
Basilar Artery Insufficiency Benign Essential Hypertension
Benign Hypertensive Renal Disease Bladder Cancer
Bleeding Disorder, Platelet-Type, 11 Blepharitis
Bronchiectasis Bronchitis
Bronchopneumonia Bullous Pemphigoid
Candidiasis Cardiac Arrest
Cardiogenic Shock Cecal Benign Neoplasm

Graphical network of the top 20 diseases related to Deficiency Anemia:



Diseases related to Deficiency Anemia

Symptoms & Phenotypes for Deficiency Anemia

UMLS symptoms related to Deficiency Anemia:


angina pectoris; chest pain; edema

MGI Mouse Phenotypes related to Deficiency Anemia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.2 EPO FOXP3 G6PD GATA1 HAMP HBA1
2 liver/biliary system MP:0005370 10.07 EPO FOXP3 GATA1 HAMP HBB NRAS
3 cellular MP:0005384 10 EPO FOXP3 G6PD GATA1 HBA1 HBA2
4 hematopoietic system MP:0005397 9.97 EPO FOXP3 G6PD GATA1 HAMP HBA1
5 mortality/aging MP:0010768 9.8 EPO FOXP3 G6PD GATA1 HAMP HBA1
6 integument MP:0010771 9.28 FOXP3 GATA1 HBA1 HBA2 HBB NRAS

Drugs & Therapeutics for Deficiency Anemia

PubMed Health treatment related to Deficiency Anemia: 63

Treatment for anemia depends on the type, cause, and severity of the condition. Treatments may include dietary changes or supplements, medicines, procedures, or surgery to treat blood loss.

Drugs for Deficiency Anemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 681)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Iron protein succinylate Approved, Investigational Phase 4 250705-13-6
2
Proguanil Approved Phase 4 500-92-5 4923 6178111
3
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
4
Halofantrine Approved Phase 4 69756-53-2 37393
5
Artenimol Approved, Experimental, Investigational Phase 4 71939-50-9 540327
6
Piperaquine Approved, Experimental, Investigational Phase 4 4085-31-8
7
Cinacalcet Approved Phase 4 226256-56-0 156419
8
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4
9
Amodiaquine Approved, Investigational Phase 4 86-42-0 2165
10
Artesunate Approved, Investigational Phase 4 88495-63-0 6917864 5464098
11
Ferrous gluconate Approved Phase 4 299-29-6
12
Carbetocin Approved, Investigational Phase 4 37025-55-1 16681432
13
Methylergometrine Approved Phase 4 113-42-8 8226
14
Quinidine Approved, Investigational Phase 4 56-54-2, 130-95-0, 804-63-7 1065 441074 3034034 8549
15
Artemether Approved Phase 4 71963-77-4 68911 9796294
16
Lumefantrine Approved Phase 4 82186-77-4 6437380
17
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
18
Sulfamethoxazole Approved Phase 4 723-46-6 5329
19
Hydromorphone Approved, Illicit Phase 4 466-99-9, 71-68-1 5284570
20
Zoledronic acid Approved Phase 4 118072-93-8 68740
21
Etonogestrel Approved, Investigational Phase 4 54048-10-1 6917715
22
Desogestrel Approved Phase 4 54024-22-5 40973
23
Iron isomaltoside 1000 Approved, Investigational Phase 4 1370654-58-2
24
Lactitol Approved, Investigational Phase 4 585-86-4 157355
25
Luspatercept Approved, Investigational Phase 4 1373715-00-4
26
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
27
Dapagliflozin Approved Phase 4 461432-26-8 9887712
28
Albendazole Approved, Vet_approved Phase 4 54965-21-8 2082
29
Ferrous succinate Approved Phase 4 10030-90-7
30
Deferasirox Approved, Investigational Phase 4 201530-41-8 214348 5493381
31
Ferrous fumarate Approved Phase 4 141-01-5
32
Ferric maltol Approved Phase 4 33725-54-1
33
Deferiprone Approved Phase 4 30652-11-0 2972
34
Ribavirin Approved Phase 4 36791-04-5 37542
35
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
36
Ibuprofen Approved Phase 4 15687-27-1 3672
37
Diamorphine Approved, Illicit, Investigational Phase 4 561-27-3 5462328
38
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
39
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 5283731
40
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453
41
Arginine Approved, Investigational, Nutraceutical Phase 4 74-79-3 6322
42
L-Glutamine Approved, Investigational, Nutraceutical Phase 4 56-85-9 5961
43
Lactoferrin Investigational Phase 4 151186-19-5
44
(3-Carboxy-2-(R)-Hydroxy-Propyl)-Trimethyl-Ammonium Experimental Phase 4 461-06-3
45 N-Methylaspartate Phase 4
46 Hydroxycholecalciferols Phase 4
47
Chondroitin Phase 4 9007-27-6 14389182
48 Zinc Supplement Phase 4
49 Teferrol Phase 4
50 Caseins Phase 4

Interventional clinical trials:

(show top 50) (show all 3341)
# Name Status NCT ID Phase Drugs
1 The Role Of IV Iron (Ferric Carboxymaltose) And IM Vitamin B12 (Hydroxycobalamin) Supplementation In The Management Of Anaemic Prevalent Indian Hemodialysis Patients: A Parallel Group, Quadruple Blind, Placebo-Controlled, Pragmatic Randomized Control Trial With 2x2 Factorial Design Unknown status NCT04627181 Phase 4 Ferric carboxymaltose;Hydroxycobalamin;Placebo
2 A Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life, and Resource Utilization of Injectafer vs. Intravenous Iron Standard of Care for the Treatment of Iron Deficiency Anemia (IDA) in an Infusion Center Setting Unknown status NCT01950247 Phase 4 Injectafer;SOC
3 Effectiveness of Weekly and Daily Iron Supplementation for the Prevention of Iron-deficiency Anemia in Infants. Impact on Genomic Stability Unknown status NCT03359447 Phase 4 Weekly Ferrous Sulfate;Daily Ferrous Sulfate
4 Different Doses of Anti-thymocyte Globin With 2.5 or 3.75mg/kg to Treat Child Severe Aplastic Anemia Unknown status NCT01997372 Phase 4 ATG
5 Does Eradication of H-pylori in Pregnant Patients With Iron Deficiency Anemia Have an Effect on Iron Replacement Therapy? Unknown status NCT03347513 Phase 4 triple attack therapy;Ferrous(II)-glycine-sulphate complex 567.7 mg capsules
6 Randomized Cross-Over Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With Inflammatory Bowel Disease Unknown status NCT02774057 Phase 4 Captafer®;Iron Sulfate
7 Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic Anemia Unknown status NCT01995331 Phase 4 cyclophosphamide,cyclosporine A
8 Amino Acid Chelated Iron Versus Ferrous Fumarate in the Treatment of Iron Deficiency Anemia With Pregnancy: Randomized Controlled Trial Unknown status NCT03830034 Phase 4 Amino Acid chelated iron tab 15 mg;Ferrous Fumarate tab 350 mg( 115 mg elemental iron)
9 The Impact of Treatment of Anaemia With Intravenous Iron on Haematological Values for Patients After Colorectal Surgery Unknown status NCT02999217 Phase 4 Iron isomaltoside;Saline
10 Tacrolimus Treatment for Refractory Autoimmune Cytopenia Unknown status NCT03918265 Phase 4 Tacrolimus
11 Effektivität Der in Der Schwangerschaftsvorsorge routinemässig Angewandten Eisenprophylaxe Unknown status NCT02487719 Phase 4 Iron sulfate and Iron polymaltose for prevention of iron deficiency anemia
12 Randomized, Parallel Group, Clinical Trial Comparing Intravenous Iron Sucrose Versus Oral Ferrous Sulphate in the Treatment of Perioperative Iron Deficiency in Patients With Colo-Rectal Neoplasm and Iron Deficiency Anemia. Unknown status NCT00199277 Phase 4 i.v. iron sucrose;Oral iron
13 Long-term Safety and Efficacy Study of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias Unknown status NCT02443545 Phase 4 Deferiprone
14 Bovine Lactoferrin Versus Ferrous Sulphate In The Treatment Of Iron Deficiency Anemia During Pregnancy: A Randomized Controlled Trial Unknown status NCT03202615 Phase 4 F (ferrous sulphate)
15 Multi-center Clinical Study of Immunosuppressants, Cyclophosphamide, And Cord Blood Transfusion in Treating Patients With Severe Aplastic Anemia Unknown status NCT02838992 Phase 4 Rabbit ATG, (Genzyme);Cy;CsA
16 the Effectiveness of Lactoferrin in Treatment of Iron Deficiency Anemia in Children With Chronic Tonsillitis Unknown status NCT03748043 Phase 4 Lactoferrin;Ferric Hydroxide Polymaltose
17 Phase 4 Study on the Efficacy of Erythropoietin Treatment in Patients With Systolic Left Ventricular Dysfunction, Mild Anemia and Normal Renal Function Unknown status NCT00418119 Phase 4 erythropoietin
18 Ferritin Screening And IRon Treatment for Maternal Anemia and Fetal Growth Restriction (FGR) Prevention - a Multi Centre Randomised Controlled Trial (RCT) Unknown status NCT04228627 Phase 4 Parentral Iron
19 Anemia Treatment in Inflammatory Bowel Disease: Predictive Factors of Response to Oral Iron Treatment Unknown status NCT02760940 Phase 4 oral liposomal iron
20 Efficacy and Safety of Erythropoietin in the Treatment of Anemia in Patients With Lymphoma After Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT03010579 Phase 4 erythropoietin;iron supplementation
21 Investigation of Signal Pathway Induced by Colla Corri Asini Regulating Globin Level in Beta Thalassemia Patients With Pregnancy Anemia Unknown status NCT03392298 Phase 4 Colla corii asini
22 Intravenous Iron Isomaltoside 1000 (Monofer®) Compared With Oral Iron in the Treatment of Postgastrectomy Anemia: An Open-label Randomized Controlled Trial Unknown status NCT03229954 Phase 4 iron isomaltoside (Monofer) intravenous infusion;Ferrous sulfate(Feroba-YOU) per oral
23 Efficacy and Safety of Intravenous Iron Sucrose in Patients With Hip Fracture to Prevent Perioperative Anemia Unknown status NCT01084122 Phase 4 Iron sucrose
24 Treatment of Anemia in the 2nd Year of Life. Comparison of the Efficacy of Two Different Iron Preparations. Unknown status NCT00248716 Phase 4 Ferrous gluconate and iron polysaccharide complex
25 A Multi-center Randomized, Double-blind, Placebo-controlled Study of Colla Corii Asini for the Treatment of Anemia in Pregnant Women With Thalassemia(Presenting the Syndrome of Blood Deficiency) Unknown status NCT03374111 Phase 4 Colla corii asini;a Simulate Agent of Colla corii asini granule
26 Evaluation of the Efficacy in Decreasing Iron Absorption in Patients With Congenital Dyserythropoietic Anemia Type I by Treatment With LOSEC Unknown status NCT01795794 Phase 4 omeprazole
27 Child With Severe Aplastic Anemia (SAA) Therapy: the Injection of Umbilical Cord Derived Mesenchymal Stem Cells. Unknown status NCT02218437 Phase 4 MSC+ATG
28 Preoperative, Single-dose Intravenous Iron Formulation to Reduce Post-surgical Complications in Patients Undergoing Major Abdominal Surgery: a Pilot Randomised Control Trial (PIRCAS Trial - Pilot) Unknown status NCT03295851 Phase 4 Ferric carboxymaltose;Ferrous Fumarate
29 The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalasemia Major Unknown status NCT02984475 Phase 4 Metformin
30 An Pilot Study to Assess the Efficacy of Intravenous Iron Isomaltoside 1000 (Monofer®) in the Management of Anaemia Associated With the Palliative Management of Oesophagogastric Adenocarcinoma Unknown status NCT01927328 Phase 4 Iron isomaltoside 1000
31 Effectiveness of Iron Supplementation in the Second Year of Life for Prevention of Iron Deficiency Unknown status NCT00479102 Phase 4 Ferripel-3 - iron polysaccharide complex for prevention
32 Multicenter Randomized Controlled Trial Comparing Ferric(III)Carboxymaltose Infusion With Oral Iron Suppletion in the Treatment of Preoperative Anaemia in Colorectal Cancer Patients Unknown status NCT02243735 Phase 4 Ferrous fumarate;ferric(III)carboxymaltose
33 A Randomized Controlled Trial of Oral and Intravenous Tranexamic Acid in Lumbar Spine Surgery Unknown status NCT03037515 Phase 4 Tranexamic Acid
34 Effect of Postoperative Ferric Carboxymaltose After Simultaneous Bilateral Total Knee Arthroplasty : A Randomized, Controlled, Double-Blind Trial Unknown status NCT03561480 Phase 4 Ferric carboxymaltose;0.9% Normal Saline
35 Evaluation of the Effects of L-Carnitine Injection in Patients Undergoing Hemodialysis Unknown status NCT00173706 Phase 4 L-Carnitine Injection
36 Intermittent Treatment With Sulfadoxine-Pyrimethamine for Malaria Control in Children: A Randomised, Double Blind, and Placebo-Controlled Clinical Trial Unknown status NCT00168948 Phase 4 Sulfadoxin (12.5) Pyrimethamine (250 mg)
37 The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients Unknown status NCT00247507 Phase 4 acetylcysteine
38 Effect of Preoperative Ferric Carboxymaltose After Simultaneous Bilateral Total Knee Arthroplasty : A Randomized, Controlled, Double-Blind Trial Unknown status NCT03561506 Phase 4 Ferric carboxymaltose;0.9% Normal Saline
39 The Effect of a Nutrient Fortified Oat Drink on Iron, Zinc, Vitamin A, and Vitamin C Status Among Filipino Children Unknown status NCT01418898 Phase 4
40 The Impact of Intermittent Preventive Malaria Treatment With Artemisinin Combination Therapy (ACT) on Hemoglobin, Malaria, Schistosomiasis, and School Attention Among Primary Schoolchildren in the Kassena-Nankana Districts, Ghana Unknown status NCT01459146 Phase 4 Artemether-lumefantrine combination plus albendazole;Artemether-lumefantrine plus Praziquantel plus Albendazole;Albendazole plus Praziquantel
41 The Effect of Intra Venus Ferric Carboxymaltose Preoperative on Hemoglobin and Blood Transfusion Post Cardiac Surgery Unknown status NCT02939794 Phase 4 Ferinject;Placebo
42 Effect of Iron Supplementation on Psychomotor Development of Non-anemic Exclusively or Predominantly Breastfed Infants: Randomized, Double-blind, Placebo-controlled Trial. Unknown status NCT02242188 Phase 4 Iron
43 A Randomized, Double-blind, Multi-center Clinical Trial Prospectively Evaluating Iron Protein Succinylate Oral Solution in Treating Patients With Chronic Heart Failure and Iron Deficiency Unknown status NCT03344523 Phase 4 Iron protein succinylate oral solution
44 Combination With Intravenous Iron Supplementation or Doubling Erythropoietin Dose for Patients With Chemotherapy-induced Anaemia Inadequately Responsive to Initial Erythropoietin Treatment Alone Unknown status NCT02731378 Phase 4 Erythropoietins (EPO);Aggressive iron dextran supplementation;Sustained iron dextran supplementation
45 Endothelial Monocyte-activating Polypeptide-II as an Endothelial Dysfunction Marker and Its Relation to the Oxidative Stress in Egyptian Sickle Patients Unknown status NCT03903133 Phase 4 Vitamin E
46 a Randomized Control Trial to Assess the Effect of Early vs Routine Iron Supplementation on Iron Store and Growth in Term Small for Gestational Age and Appropriate for Gestational Age Infants at 1 Year Unknown status NCT03171324 Phase 4 Iron Supplement
47 Iron Deficiency as an Ignored Cause of Infertility Unknown status NCT04510870 Phase 4 Ferric Carboxymaltose Injection;NaCl infusion
48 Effect of Mobile-Directly Observed Therapy (DOT) on Adherence to Hydroxyurea Treatment in Adult HbSS Patients at Muhimbili National Hospital (MNH) in Tanzania: a Pilot Study Unknown status NCT02844673 Phase 4 Hydroxyurea
49 Megadose of Hydroxocobalamin (Vitamin B12) for the Treatment of Pernicious Anemia Completed NCT03372447 Phase 4 Hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg
50 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 (Stoss Therapy) in Pediatric Patients Undergoing HSCT to Prevent Vitamin D Deficiency and Insufficiency During Transplant Completed NCT03176849 Phase 4

Search NIH Clinical Center for Deficiency Anemia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


darbepoetin alfa
Epoetin Alfa
Nandrolone
nandrolone decanoate
nandrolone phenpropionate
Oxymetholone
Sodium Ascorbate

Cochrane evidence based reviews: anemia

Genetic Tests for Deficiency Anemia

Genetic tests related to Deficiency Anemia:

# Genetic test Affiliating Genes
1 Anemia 28

Anatomical Context for Deficiency Anemia

Organs/tissues related to Deficiency Anemia:

MalaCards : Bone Marrow, Kidney, Heart, Colon, Bone, Lung, Myeloid

Publications for Deficiency Anemia

Articles related to Deficiency Anemia:

(show top 50) (show all 65753)
# Title Authors PMID Year
1
Biosimilar erythropoietin in anemia treatment (BEAT)-Efficacy and safety of a 1:1 dose conversion from EPREX® to EPIAO® in patients with end-stage renal disease on hemodialysis: A prospective, randomized, double blind, parallel group study. 62 41
36451454 2022
2
Whole-genome sequencing of patients with rare diseases in a national health system. 5
32581362 2020
3
Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses. 41
36124924 2022
4
Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma. 41
36330523 2022
5
Ribosomal protein S19 binds to its own mRNA with reduced affinity in Diamond-Blackfan anemia. 53 62
20395159 2010
6
Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin. 53 62
20406921 2010
7
The influence of the aziridinyl substituent of benzimidazoles and benzimidazolequinones on toxicity towards normal and Fanconi anaemia cells. 53 62
20122765 2010
8
Evidence of receptor-mediated elimination of erythropoietin by analysis of erythropoietin receptor mRNA expression in bone marrow and erythropoietin clearance during anemia. 53 62
20103588 2010
9
Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV - the role of epoetin, G-CSF and novel agents. 53 62
20175767 2010
10
Low-density lipoprotein apheresis decreases ferritin, transferrin and vitamin B12, which may cause anemia in serially treated patients. 53 62
20438534 2010
11
Hematological predictors of increased severe anemia in Kenyan children coinfected with Plasmodium falciparum and HIV-1. 53 62
20196168 2010
12
Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease. 53 62
20470305 2010
13
Pharmacodynamic effects of haematopoietic cytokines: the view of a clinical oncologist. 53 62
20050838 2010
14
The first case of a class I glucose-6-phosphate dehydrogenase deficiency, G6PD Santiago de Cuba (1339 G > A), in a Chinese population as found in a survey for G6PD deficiency in northeastern and central China. 53 62
20200584 2010
15
Iron regulatory hormone hepcidin decreases in chronic heart failure patients with anemia. 53 62
20019408 2010
16
Growth differentiation factor 15 in anaemia of chronic disease, iron deficiency anaemia and mixed type anaemia. 53 62
19863534 2010
17
Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib. 53 62
19920817 2010
18
Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. 53 62
19854855 2010
19
Absence of truncating BRIP1 mutations in chromosome 17q-linked hereditary prostate cancer families. 53 62
19935797 2009
20
[Soluble tranferrin receptor in the biological diagnosis of iron deficiency. Report of 24 cases]. 53 62
20209848 2009
21
Hemolytic anemia after zopiclone overdose. 53 62
19821637 2009
22
The use of real-time PCR technique in the detection of novel protein 4.2 gene mutations that coexist with thalassaemia alpha in a single patient. 53 62
19508687 2009
23
Hemochromatosis gene mutations and treatment of anemia in patients on hemodialysis. 53 62
19732172 2009
24
[Erythropoietin treatment of infants with anaemia in the first three months of life]. 53 62
20081275 2009
25
Serum transferrin receptors: Distribution and diagnostic performance in pre-school children. 53 62
19394251 2009
26
MRE11-RAD50-NBS1 is a critical regulator of FANCD2 stability and function during DNA double-strand break repair. 53 62
19609304 2009
27
Novel beta-spectrin mutations in hereditary spherocytosis associated with decreased levels of mRNA. 53 62
19538529 2009
28
'Microalbuminuric anaemia'--the relationship between haemoglobin levels and albuminuria in diabetes. 53 62
19481284 2009
29
MIF (macrophage migration inhibitory factor) promoter polymorphisms and susceptibility to severe malarial anemia. 53 62
19591577 2009
30
Naturally acquired hemozoin by monocytes promotes suppression of RANTES in children with malarial anemia through an IL-10-dependent mechanism. 53 62
19427395 2009
31
Adult onset Stills disease in a tertiary care hospital of Pakistan. 53 62
19579736 2009
32
Replication stress induces sister-chromatid bridging at fragile site loci in mitosis. 53 62
19465922 2009
33
Time course of anemia during six months follow up following intensive care discharge and factors associated with impaired recovery of erythropoiesis. 53 62
19384207 2009
34
[Anemia in hospitalized patients with cirrhosis: prevalence, clinical relevance and predictive factors]. 53 62
19663083 2009
35
Haemolysis during diabetic ketoacidosis treatment in two girls with incomplete glucose-6-phosphate dehydrogenase deficiency. 53 62
19705624 2009
36
Therapy-resistant anaemia in congenital nephrotic syndrome of the Finnish type--implication of EPO, transferrin and transcobalamin losses. 53 62
19153070 2009
37
Multisystemic sarcoidosis associated with a second therapy for chronic hepatitis C. 53 62
19637783 2009
38
Causes and consequences of inflammation on anemia management in hemodialysis patients. 53 62
19432697 2009
39
Role of interleukin-6 in the anemia of chronic disease. 53 62
18336871 2009
40
[Systemic lupus erythematosus over hemophagocytic lymphohistiocytosis]. 53 62
19432029 2009
41
Assessment of iron and zinc intake and related biochemical parameters in an adult Mediterranean population from southern Spain: influence of lifestyle factors. 53 62
18547795 2009
42
Normal thiopurine methyltransferase phenotype testing in a Crohn disease patient with azathioprine induced myelosuppression. 53 62
19356188 2009
43
Baseline characteristics of an incident haemodialysis population in Spain: results from ANSWER--a multicentre, prospective, observational cohort study. 53 62
19028750 2009
44
Current controversies in the management of the anemia of prematurity. 53 62
19167579 2009
45
Novel models of cancer-related anemia in mice inoculated with IL-6-producing tumor cells. 53 62
19265263 2009
46
[Clinical reasoning and decision making in clinical practice: a boy with fatigue and abdominal pain]. 53 62
19785903 2009
47
Perioperative indocyanine green clearance is predictive for prolonged intensive care unit stay after coronary artery bypass grafting--an observational study. 53 62
19747406 2009
48
[Density-specific distribution of erythrocytes in different types of anemia]. 53 62
19253711 2009
49
Genetic variation on chromosome 6 influences F cell levels in healthy individuals of African descent and HbF levels in sickle cell patients. 53 62
19148297 2009
50
[Molecular factors of angiogenesis in renal tissue of patients with chronic glomerulonephritis: association with nephrosclerosis and anemia]. 53 62
19799194 2009

Variations for Deficiency Anemia

ClinVar genetic disease variations for Deficiency Anemia:

5 (show all 18)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 overlap with 6 genes NG_000007.3:g.63632_71046del DEL Pathogenic
15061 GRCh37: 11:5247800-5255214
GRCh38: 11:5226570-5233984
2 LOC106099062, HBB, LOC107133510 NM_000518.5(HBB):c.79G>A (p.Glu27Lys) SNV Pathogenic
15161 rs33950507 GRCh37: 11:5248173-5248173
GRCh38: 11:5226943-5226943
3 TTR NM_000371.4(TTR):c.424G>A (p.Val142Ile) SNV Pathogenic
13426 rs76992529 GRCh37: 18:29178618-29178618
GRCh38: 18:31598655-31598655
4 FOXP3 NM_014009.4(FOXP3):c.1190G>A (p.Arg397Gln) SNV Pathogenic
379222 rs1057520529 GRCh37: X:49107901-49107901
GRCh38: X:49251440-49251440
5 HBA1, LOC106804612, HBA2 NM_000517.6(HBA2):c.410T>C (p.Leu137Pro) SNV Pathogenic
15655 rs41469945 GRCh37: 16:223580-223580
GRCh38: 16:173581-173581
6 LOC106099062, HBB, LOC107133510 NM_000518.5(HBB):c.20A>T (p.Glu7Val) SNV Pathogenic
15333 rs334 GRCh37: 11:5248232-5248232
GRCh38: 11:5227002-5227002
7 MT-ATP6, MT-ATP8 NC_012920.1:m.8570T>C SNV Likely Pathogenic
869162 rs2068710214 GRCh37: MT:8570-8570
GRCh38: MT:8570-8570
8 RPS26 NM_001029.5(RPS26):c.312+2T>A SNV Likely Pathogenic
812897 rs1593023809 GRCh37: 12:56437279-56437279
GRCh38: 12:56043495-56043495
9 GATA1 NM_002049.4(GATA1):c.680C>T (p.Ala227Val) SNV Likely Pathogenic
812972 rs1602220307 GRCh37: X:48650811-48650811
GRCh38: X:48792404-48792404
10 overlap with 171 genes DEL Likely Pathogenic
812956 GRCh37: 11:114433313-131230466
GRCh38:
11 RPL11 NM_000975.5(RPL11):c.142_143dup (p.Val49fs) DUP Likely Pathogenic
812883 rs1570566714 GRCh37: 1:24019231-24019232
GRCh38: 1:23692741-23692742
12 NRAS NM_002524.5(NRAS):c.176C>A (p.Ala59Asp) SNV Likely Pathogenic
812886 GRCh37: 1:115256535-115256535
GRCh38: 1:114713914-114713914
13 SPTA1 NM_003126.4(SPTA1):c.2464+1G>A SNV Likely Pathogenic
812890 rs774632615 GRCh37: 1:158632491-158632491
GRCh38: 1:158662701-158662701
14 ITGA3 NM_002204.4(ITGA3):c.1766G>C (p.Arg589Pro) SNV Uncertain Significance
1339481 GRCh37: 17:48153781-48153781
GRCh38: 17:50076417-50076417
15 GATA2 NM_032638.5(GATA2):c.971A>G (p.Lys324Arg) SNV Uncertain Significance
523417 rs1480450110 GRCh37: 3:128202749-128202749
GRCh38: 3:128483906-128483906
16 SHH NM_000193.4(SHH):c.86G>C (p.Gly29Ala) SNV Uncertain Significance
1338810 GRCh37: 7:155604731-155604731
GRCh38: 7:155812037-155812037
17 YARS1 NM_003680.4(YARS1):c.611A>C (p.Tyr204Ser) SNV Uncertain Significance
986742 rs1217293329 GRCh37: 1:33256836-33256836
GRCh38: 1:32791235-32791235
18 ANK1 NM_000037.4(ANK1):c.1948A>G (p.Met650Val) SNV Uncertain Significance
373944 rs1057518790 GRCh37: 8:41566346-41566346
GRCh38: 8:41708828-41708828

Expression for Deficiency Anemia

Search GEO for disease gene expression data for Deficiency Anemia.

Pathways for Deficiency Anemia



Pathways directly related to Deficiency Anemia:

# Pathway Source
1 Defective TBXAS1 causes GHDD Reactome 66

GO Terms for Deficiency Anemia

Cellular components related to Deficiency Anemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 blood microparticle GO:0072562 9.86 TFRC HBB HBA2 HBA1
2 cytosolic small ribosomal subunit GO:0022627 9.8 RPS26 HBA2 HBA1
3 endocytic vesicle lumen GO:0071682 9.63 HBB HBA2 HBA1
4 proton-transporting ATP synthase complex, coupling factor F(o) GO:0045263 9.54 MT-ATP8 MT-ATP6
5 hemoglobin complex GO:0005833 9.43 HBB HBA2 HBA1
6 haptoglobin-hemoglobin complex GO:0031838 9.1 HBB HBA2 HBA1

Biological processes related to Deficiency Anemia according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 aging GO:0007568 10.03 TFRC MT-ATP6 HAMP EPO
2 cellular iron ion homeostasis GO:0006879 9.95 TMPRSS6 TFRC HAMP
3 positive regulation of cell death GO:0010942 9.88 HBB HBA2 HBA1
4 response to hydrogen peroxide GO:0042542 9.85 HBA1 HBA2 HBB
5 myeloid cell homeostasis GO:0002262 9.81 HAMP FOXP3
6 acute-phase response GO:0006953 9.8 TFRC HAMP EPO
7 myeloid cell apoptotic process GO:0033028 9.76 GATA1 EPO
8 hydrogen peroxide catabolic process GO:0042744 9.73 HBB HBA2 HBA1
9 negative regulation of myeloid cell apoptotic process GO:0033033 9.67 GATA1 EPO
10 oxygen transport GO:0015671 9.63 HBB HBA2 HBA1
11 carbon dioxide transport GO:0015670 9.43 HBB HBA2 HBA1
12 nitric oxide transport GO:0030185 9.1 HBB HBA2 HBA1

Molecular functions related to Deficiency Anemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peroxidase activity GO:0004601 9.8 HBB HBA2 HBA1
2 oxygen binding GO:0019825 9.73 HBB HBA2 HBA1
3 oxygen carrier activity GO:0005344 9.63 HBB HBA2 HBA1
4 organic acid binding GO:0043177 9.43 HBB HBA2 HBA1
5 haptoglobin binding GO:0031720 9.1 HBB HBA2 HBA1

Sources for Deficiency Anemia

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....